The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The shot mixes the antigenic components of GSK’s established meningococcal vaccines Bexsero and Menveo, which target MenB and MenACWY, respectively, to offer broader coverage in fewer doses.

The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

Penmenvy is a combination of GSK's already-approved vaccines Bexsero and Menveo, which together brought in more than £1.4 billion (around $1.8 billion) in sales last year with double-digit growth ...

Noninferiority was observed with Penmenvy vs 2 doses of Bexsero for the proportion of ... with a single dose of Menveo in both MenACWY vaccine-naïve participants and MenACWY vaccine-experienced ...

GSK’s Penmenvy combines the antigenic components of its approved Bexsero and Menveo meningococcal vaccines to target five common IMD-causing serotypes (A, B, C, W and Y). It is hoped that the ...

Vaccine helps protect against five common disease ... Important Safety Information for BEXSERO in the US The following is based on the US Prescribing Information for BEXSERO.

The vaccine, branded as Penmenvy, combines components from two of GSK’s existing vaccines: Bexsero, which protects against serogroup B; and Menveo, which protects against serogroup A ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

TUESDAY, Feb. 18, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive ...